The reduced efficacy in the Redd1−/− mice was correlated with significant decreases in CD31+ tumor vessel density, caspase-3 activation, and TUNEL-positive apoptosis (Fig. 5b and c; Supplementary Fig. 6c–f). The gene discussed is CASP3; the disease is neoplasm.